PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.47%
Both companies show declining cash positions (-7.47% vs RVPH's -21.11%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.47%
Below half of RVPH's -21.11%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.14%
Below half of RVPH's -19.54%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-20.34%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.34%
Below half of RVPH's -100.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-7.25%
Below half of RVPH's -19.54%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-4.95%
Less than half of RVPH's 179.80%. David Dodd sees a more disciplined AP approach or lower volume.
-36.48%
Higher Short-Term Debt Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-627.15%
Both RVPH and the company show zero Deferred Revenue (Current) Growth.
-89.58%
Less than half of RVPH's 19.75%. David Dodd sees fewer expansions in other current obligations.
-16.33%
Less than half of RVPH's 54.53%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-33.33%
1.25-1.5x RVPH's -23.88%. Martin Whitman is wary of heavier future burdens.
No Data
No Data available this quarter, please select a different quarter.
-16.34%
Less than half of RVPH's 43.78%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.01%
Below half RVPH's -11.02%. Michael Burry suspects major net losses or high dividends vs. competitor.
100.00%
Higher AOCI Growth compared to RVPH's zero value, indicating worse performance.
-100.00%
Less than half of RVPH's 0.04%. David Dodd notes simpler yoy equity changes vs. competitor.
-6.40%
Below half RVPH's -25.54%. Michael Burry sees potential underperformance in building shareholder capital.
-7.25%
Below half RVPH's -19.54%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-36.45%
Higher Total Debt Growth compared to RVPH's zero value, indicating worse performance.
7.35%
Less than half of RVPH's 21.11%. David Dodd sees better deleveraging or stronger cash buildup than competitor.